Australia TGA Issues a Notice on Transition to New GMP Requirements for Medicinal Products

Therapeutic Goods Administration(TGA) of Australia will adopt the current version of the PIC/S Guide to Good Manufacturing Practice for Medicinal Products PE009-14 (PIC/S Guide to GMP), excluding Annexes 4, 5 and 14, as the manufacturing principles for medicines and active pharmaceutical ingredients, with effect from 1 July 2020 . This will replace the manufacturing principles adopted in 2018 by the TGA for the manufacture of medicines, active pharmaceutical ingredients, and sunscreens: the PIC/S Guide to Good Manufacturing Practice for Medicinal Products PE009-13.

This notice is being issued to assist with the transition period. It is a point-in-time document and TGA is not planning on updating this notice. TGA will be updating GMP guidance during 2020 to reflect the new requirements. The notice contains a summary table of new and amended GMP requirements and a transition period from 1 July 2020 to 1 July 2021 to allow manufacturers to assess and plan for these changes and permit time for implementation.

TGA’s expectation is that by 1 January 2021, manufacturers will have:
• completed their assessment of the impact of the new manufacturing principles on their operations; and
• completed, or be well advanced, towards updating quality systems documentation and implementing revised practices

Further information pertaining to the guideline could be referred to

Share on Linkedin Send to Email

Questions? Request more information from our specialists!

Contact Us

More News